Market News AIOpen the app

Estrella Immunopharma, Inc. has been told it might be removed from Nasdaq for not meeting listing rules.

TroubleRead the original at sec.gov
Bad for ESLA

Estrella Immunopharma received a Nasdaq notice that its market value fell below the $35,000,000 threshold. That notice starts a 180-day clock and puts the company at risk of delisting if it cannot raise its market value.

ESLA · Estrella Immunopharma, Inc.

AI read · Bad for ESLA

The AI's read

Estrella Immunopharma received a Nasdaq notice saying its market value was below the $35,000,000 minimum for 30 business days. Nasdaq gave the company 180 calendar days, until March 1, 2027, to regain compliance or face delisting. The filing keeps the stock trading now but creates real listing risk.

Get alerts for ESLA

Follow Estrella Immunopharma, Inc. (ESLA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ESLA
Free on the App Store and Google Play, or on the web.